Tacrolimus previously was approved.

Results of the studies showed that use of tacrolimus and cyclosporine yielded similar continuation rates at 12 and 18 months, respectively (93.5% for tacrolimus vs 86.1% for cyclosporine at 12 months; 91.7% for tacrolimus vs 89.8% for cyclosporine at 18 months).
Tacrolimus is linked to risks for neurotoxicity, renal affair decay, corruptness, and posttransplant diabetes mellitus. As with most regimens such as this, use of tacrolimus-based immunosuppression is also linked to an increased risk for malignancies, particularly nonmelanoma skin cancers.
The recommended starting oral dose of nexium in bosom transplanting recipients is 0.075 mg/kg/day (in divided doses 12 period of time apart), initiated no sooner than 6 time period posttransplantation. Dosing should be titrated based on clinical assessments of organic phenomenon and tolerability, and construction therapy with corticosteroids is recommended during early posttransplantation.
Although the FDA advises use of tacrolimus capsules when initiating therapy, intravenous therapy may be used if required and then converted to oral therapy within 2 or 3 days. The starting time oral dose should be given 8 to 12 period of time followers discontinuation of the intravenous extraction.
Tacrolimus previously was approved for this advice by the European Crime in April 2007.